![FDA, FTC and DOJ Enforcement of Medical Device Regulations FDA, FTC and DOJ Enforcement of Medical Device Regulations](https://www.fdanews.com/ext/resources/Book-Covers-2/BFFDEMDR-COVER.png?height=200&t=1685733565&width=200)
Home » Adherex, NCI to Collaborate on Clinical Development of ADH-1
Adherex, NCI to Collaborate on Clinical Development of ADH-1
Adherex Technologies has announced that the Drug Development Group of the National Cancer Institute's (NCI) Division of Cancer Treatment and Diagnosis has approved a Level III collaboration for the clinical development of the company's lead biotechnology compound ADH-1, also known as Exherin, provided additional preclinical studies be conducted.
The NCI, which is part of the NIH, approved a collaboration with Adherex following the formal review of existing preclinical and clinical data on ADH-1. As part of the collaboration, the NCI's developmental therapeutics program and cancer therapy evaluation program will negotiate a cooperative research and development agreement (CRADA) with Adherex to sponsor clinical trials and additional preclinical studies of ADH-1.
These studies will further evaluate its anticancer and vascular targeting effects, both as a single agent and in combination with other agents in patients with advanced resistant cancers that express the molecular target N-cadherin. The exact design of the trials to be sponsored by the NCI will be determined after the execution of the CRADA.
KEYWORDS Drug Pipeline Alert
Upcoming Events
-
11Jul
-
18Jul
-
21Oct